Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine
|
|
- Collin George
- 8 years ago
- Views:
Transcription
1 Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine Joel R. Saper, M.D., 1 Stephen D. Silberstein, M.D., 2 Alvin E. Lake III, Ph.D., 1 Marjorie E. Winters, R.N., B.S.N. 1 1 Michigan Head-Pain and Neurological Institute, Ann Arbor, Michigan 2 Comprehensive Headache Center, Germantown Hospital and Medical Center, Philadelphia, Pennsylvania. Address all correspondence to Joel R. Saper, M.D., F.A.C.P., Michigan Head-Pain and Neurological Institute, 3120 Professional Drive, Ann Arbor, MI Accepted for publication March 26, SYNOPSIS This study is the first double-blind placebo-controlled trial of fluoxetine for chronic daily headache (CDH) and migraine. After a one month single-blind baseline on placebo, subjects with CDH (n=64) and migraine (n=58) were randomly assigned to a three month trial of fluoxetine (20 mg) or an identical placebo. Fluoxetine and placebo were increased to 40 mg in the second month, depending on patient response. Patients kept daily headache records, and completed 100 mm visual analogue scales (VAS) of headache and mood each month. For the group of CDH patients on fluoxetine, overall headache status (VAS) after three months compared to the end of the single-blind placebo baseline improved a mean of 50% vs. 11% for those receiving the double-blind placebo ( P =.029), with 47% vs. 23% improving at least 50% (P=.097, n.s.). Fluoxetine patients showed significant improvement in monthly mood ratings compared to placebo (.001 by the end of the study), and modest but significant improvement in daily records of headache frequency (P=.019) but not pain severity. Significant mood improvements preceded improvement in headache, reaching significance by the end of the second month on fluoxetine (P=.013), while headache improvement emerged only during the third month (P=.001). Double-blind investigator judgement identified more headache improvement in fluoxetine than placebo recipients (40% vs. 22%, P=.032). Fluoxetine was not effective on any measure for migraine, with the exception of modest mood improvement at the end of the third month (P=.043). Adverse effects were more frequent but not more severe for fluoxetine, including sleep disturbance (28% vs. 8%, P=.008), tremors (20% vs. 5%, P=.025), and minor stomach pain (13% vs. 0%, P=.008). Fluoxetine appears moderately effective for CDH but not migraine, with a generally tolerable side effect profile. The influence on headache may be linked to its effect on mood. In general, study subjects were not clinically depressed. Future research might focus on subjects with comorbid depression and headache. Key words: Fluoxetine, chronic daily headache, migraine, double-blind study Abbreviations: CDH chronic daily headache, VAS visual analogue scale. (Headache 1994; 34: ) INTRODUCTION Migraine has been linked to a defect in the serotonin system, 1,2 and Raskin has identified modification of serotonergic transmission as the common denominator underlying medications shown to be effective in treating migraine? Consequently, it is reasonable to expect that a selective serotonin reuptake inhibitor such as fluoxetine might be effective in migraine prophylaxis. One brief report of an open label study of fluoxetine for headache found improvement in 59% of 64 patients who had previously been treated with antidepressants. 4 Fluoxetine has been shown to potentiate morphine analgesia. 5 Several case reports suggest the drug's potential for pain control in conditions ranging from chronic abdominal pain 6 to arthritis, 7 phantom limb pain, 8 chronic hand pain, 9 and diabetic neuropathy. 10 However, a randomized, double-blind crossover study of diabetic neuropathic pain failed to show fluoxetine to be more effective than placebo.11 In this paper we report results from two studies examining the effectiveness of fluoxetine for migraine and chronic daily headache. This work represents the first double-blind placebo-controlled evaluation of fluoxetine for head pain. METHODS Subjects. Sixty-four patients with chronic daily headache (CDH) and 58 patients with migraine were recruited at two comprehensive headache centers in Ann Arbor and Philadelphia. To be enrolled in the study, subjects had to be between 18 and 60 years of age and meet International Headache Society criteria for migraine,12 with at least a two-year headache history and 4-12 attacks per month of at least four hours duration. Chronic daily headache was defined as at least 16 headache days per month over the previous three months, which could be periodically accompanied by severe migraine attacks. Potential subjects who met the following criteria were excluded: previous unsuccessful treatment with three or more prophy-
2 lactic agents; migraine events occurring more than twice a week or where severe neurological accompaniments were present; continuing use of other prophylactic treatment or daily analgesics; unwillingness to abstain from known headache-provoking foods or other triggers; renal or hepatic dysfunction; history of eating disorder, nutritional deficits, or recent weight loss over 5 pounds; multiple drug allergies; significantly abnormal or changing neurological examinations; known severe psychological disturbance; use of investigational drugs in the preceding 35 days; known drug dependence or narcotic tolerance; pregnancy, lactation, or women of child-bearing potential not using medically acceptable contraception; use of MAOIs in the preceding four weeks; reliance on other antidepressant drugs; history of seizures; and critical illness or any major health event within the past 6 months. Measurement Instruments. Subjects and a "significant other" completed 100 mm Visual Analogue Scales (VAS) (overall headache status, headache frequency, average headache intensity, mood, and energy level) at the time of enrollment, the conclusion of the placebo washout phase, and again at 4-week intervals until the conclusion of the study, for a total of five measures for the five experimental phases. All subjects kept a daily headache diary, rating headache level four times a day on a 5-point scale.13 The headache diary was used to calculate a headache index, days per week with severe headache, and the number of headache-free days per week. At the conclusion of the study, investigators made a double-blind judgement of patient response. Patients completed the Beck Depression Inventory14 on enrollment, after the one month placebo washout, and at the end of the final month. Weight was recorded on admission and at each subsequent investigator visit at 4-week intervals. The distribution of subjects by diagnosis, treatment condition, sex, age, and Beck scores is shown in Table 1. None of the differences between fluoxetine and placebo groups were statistically significant. Study Design. The investigation was conducted at two geographically separate centers, utilizing a 16-week, randomized, double-blind, parallel-group design, with an initial 4-week single-blind placebo washout phase (baseline) beginning on visit 1 and ending on visit 2. The initial single-blind placebo condition in the experimental design requires that the drug effect be significantly greater than the initial placebo effect for patients receiving active treatment. After completing the placebo baseline, subjects were randomly assigned to active or placebo treatments. Only one member of the investigative team had access to randomization lists, and the code was not bro- Table 1. - Patient Demographics: Sex, Age, and Beck Depression Scores at Enrollment Chronic Daily Headache Migraine Fluoxetine Placebo Fluoxetine Placebo Sex Female Male Age Mean S.D Range Low High Beck Score Mean S.D Range Low High Note: Beck < 10 = Within Normal Limits. ken until all subjects had completed the study. For the remaining 12 weeks of the study, subjects received identically appearing capsules of either fluoxetine or placebo, beginning with 20 mg/day. After the second month (visit 3), if no therapeutic response had occurred but the drug was tolerated, the dose was increased to two capsules of either fluoxetine or placebo each day for the remaining eight weeks. Fluoxetine blood levels were taken at the end of month 2 (initial 20 mg dose) and month 3 (final adjusted dose up to 40 mg). The final adjusted dose of fluoxetine was 40 mg for 26 out of 29 CDH subjects (90%) and 25 out of 29 migraineurs (86%). Mean total fluoxetine blood levels at the end of month 3 were ng/ml (SD = ) for the CDH group, and ng/ml (S.D. = ) for migraine. Compliance with the prescription protocol was assessed at each monthly visit by investigator count of remaining medication. Mean compliance was greater than 94% for all diagnosis-drug combinations. Subjects were allowed to use rescue medications including Anaprox(r) or other NSAIDs, Midrin(r), or Cafergot(r), with some individual allowance of other simple or combination analgesics. Simple analgesics were limited to no more than three days per week; combination analgesics and Cafergot(r) were limited to two days per week maximum. Informed consent was obtained before subjects entered the study. This research protocol was approved by an appropriate institutional review board for participating centers. Safety Assessments/Diagnostic Tests. Laboratory screening tests included a hematology panel, chemistry, and urinalysis. All subjects completed a headache and neurological history, and received neurological examinations and electrocardiograms. Beginning with the placebo washout, patients were requested to report the type and severity of any adverse events. Statistical Analysis. Data analysis was performed with the SYSTAT statistical program for MS-DOS systems, using repeated measures analysis of variance to analyze main and interactional effects over the five experimental phases (initial enrollment, single-blind placebo, and the three months of active treatment), with post hoc paired and/or independent t-tests when the ANOVA revealed significant effects. Nonparametric tests were applied to analyses based on the number of subjects meeting selected criteria (eg double-blind investigator judgement of outcome). P values of <.050 were considered significant. RESULTS Headache. Visual Analogue Scales. For Chronic Daily Headache, repeated measures analysis of variance on Overall Headache Status revealed significant effects for phases [F(4,196)=17.61, P=.001] and a drug x phase interaction [F(4,196)=2.50, P=.044]. Post hoc analyses using paired t-tests showed that both the fluoxetine [t(29)=3.12, P=.004] and placebo groups [t(23)=4.27, P=.001] improved from enrollment until the end of the single-blind placebo phase, indicating a significant initial placebo effect. However, the primary comparisons of interest lie between the end of the single-blind placebo baseline and the active treatment phases. In this case, the only significant effect occurred for fluoxetine subjects at the conclusion of the final month of treatment (i.e. second month on the final adjusted dose) [t(49)=4.49, P=.001]. These results are depicted graphically in Figure 1.
3 For CDH patients as a group, the mean percent improvement in Overall Headache Status at the end of the study compared to the end of the single blind placebo baseline was 53% vs. 17% for double-blind placebo [t(49)= 2.18, P=.029]. Fourteen (14) of 30 fluoxetine patients (47%) improved at least 50% on this variable vs. only 5 of 21 placebo patients (24%), although this difference only approached statistical significance [X2 (1) =2.76, P=.097]. ANOVA for migraine cases revealed a significant phases effect [F(4,204) = 12.01, P=.000] but no interaction effect. Post hoc t-tests did not show any significant improvement in either the fluoxetine or placebo group after conclusion of the initial single-blind placebo. Other than the expected phases effects, none of the analyses of other headache-related VAS measures (frequency, intensity, energy level) or ratings by significant others reached significance for either diagnosis. Headache Diary. For CDH, a repeated measures analysis of variance for the number of Headache-Free Days (per week) revealed both the expected phases effect [F(3,150)=15.31, P=.001] and a drug x phase interaction [F(3,150)=3.42, P=.019]. In this case, similar increases in Headache-Free Days were observed in both the fluoxetine and placebo groups. For fluoxetine, Headache-Free Days increased from 1.57/week during the single-blind placebo baseline to 2.67 during the third month [t(28)=3.93, P=.001]; for placebo, Headache-free Days increased from 1.12/week to 2.27 [t(23)=3.72, P=.001]. ANOVAs for Headache Index and Severe Headaches/week yielded the expected significant phases effect, showing improvement for both fluoxetine and placebo over time, but no interaction effect that would support differential efficacy. For migraine, ANOVAs for Headache-Free Days, Headache Index, and Severe Days also showed significant phases effects but no significant interaction or drug effects. Double-Blind Investigator Judgement. At the conclusion of the study, investigators at each site judged patient response as improved (i.e., "good" or "fair") or unimproved ("poor") based on the information available at that time. For CDH, 25 of 30 subjects receiving fluoxetine (83%) were judged to be improved vs. only 13 of 23 subjects (57%) receiving double-blind placebo. These results were statistically significant [X2(1)=4.61, P=.032]. For migraine, 22 of 31 fluoxetine patients (71%) were judged as improved vs. 15 of 27 (56%) on placebo [X2(1)=1.48, n.s.]. Mood. Visual Analogue Scale. Repeated measures analysis of variance on VAS Mood ratings were completed, analogous to the ANOVA for Overall Headache Status. For CDH, analysis revealed a significant phases effect [F(4,196)=10.67, P=.001], and a significant drug x phases interaction [F(4,196)=2.77, P=.028] supporting differential effectiveness favoring fluoxetine. Compared to the Mood rating at the end of the single-blind placebo baseline, Mood showed significant improvement by the end of the second month on fluoxetine [t(29)=2.49, P=.019] and further improved by the end of the third month [t(28)=3.86, P=.001]. There was no significant improvement for the placebo patients beyond the initial single-blind placebo baseline. These results are depicted in Figure 2. Continuing the CDH analysis, the mean percent improvement in Mood at the end of the third month compared to the end of single-blind baseline for the group as a whole was [t(49)=2.38, P=.019]. Twelve of 29 patients on fluoxetine (41%) showed at least a 50% improvement in Mood vs. only 3 of 22 subjects (14%) on placebo [X 2 (1) =4.64, P=.031. For migraine cases, analysis revealed the expected phases effect [F(4,208)=8.49, P=.001], but no drug x phase interaction. Post-hoc analysis did show a significant improvement in Mood for migraine patients by the end of the third month
4 compared to the end of the single-blind placebo baseline [t(29)=2.12, P=.043], but no further improvement for those on double-blind placebo. Relationship of Mood to Headache Improvement. Several analyses were performed in order to assess the relationship between improvement in Mood and headache improvement. As shown in Figure 3, CDH fluoxetine subjects who demonstrated at least 50% improvement in VAS Mood ratings at the end of the second and third months were significantly more likely to demonstrate at least a 50% improvement in Overall Headache Status at the end of the study [X2(1)=9.81, P=.002; X2(1)=12.27, P=.001]. In other words, Mood improvement at the end of the second month preceded and was significantly associated with improvement in Overall Headache Status at the end of the third month. For CDH Fluoxetine patients (n=29), Pearson correlations were significant or near-significant between Headache-Free Days and Mood at the end of the month for the single-blind placebo baseline (R=.403, P=.030), month 1 (R=.526, P=.003), month 2 (R=.328, P=.083), and month 3 (R=.334, P=.076), indicating that Mood accounted for between 10.76% to 27.67% of the variance in headache-free days/week. However, there was no relationship between Mood improvement and any of the other variables from the Headache Diary. Depression. Beck Depression Inventory scores declined significantly over time for all groups, due to a significant decrease between enrollment and the end of the single-blind placebo baseline [F(2,178)=21.641, P=.001]. By the end of the baseline, the mean Beck score of 6.08 (SD=5.04) was well within normal limits (under 10), and showed no further improvement at the end of the study (mean=5.33, SD=5.21). There were no significant differences for Beck scores between diagnoses or drug treatments. Initial Beck scores did not predict treatment outcome. Comparison of Results by Treatment Center. Analyses of variance including treatment center as a factor did not reveal any significant differences in outcome for any of the dependent variables studied. Adverse Effects and Dropouts. CDH and migraine patients were combined for the analysis of adverse effects. For fluoxetine, 51 of 61 patients (84%) reported the presence of some adverse ef-
5 fects vs. 33 of 50 patients (66%) on placebo [X2(1)=4.63, P=.031]. However, for those patients reporting adverse events, the rated severity of effects did not differ significantly between groups [X2(1)=1.37,n.s.]. Only 5 of 61 fluoxetine patients (8%) reported severe adverse effects (fatigue, restlessness, sleep disturbance, stomach pain, blurred vision) compared to 2 of the 50 placebo patients (4%), a nonsignificant difference. As shown in Table 2, only three adverse effects were significantly more prevalent in the fluoxetine than placebo groups: sleep disturbance, tremors, and stomach pain. It is of interest to note that fatigue was frequently noted as a moderately disturbing adverse event by roughly equal percentages of subjects in both the fluoxetine (25%) and placebo groups (26%). Five patients on fluoxetine reported moderately disturbing weight loss from 9 to 15 pounds (mean=11.20) vs. only one placebo patient reporting a mildly disturbing weight loss of five pounds, although these differences were not statistically significant. Table 2.-Adverse Effects More Prevalent for Fluoxetine than Placebo Combined CDH and Migraine Patients Effect Drug N % P Sleep Problem Fluoxetine 17/ Placebo 11/50 8 Tremors Fluoxetine 12/ Placebo 3/50 5 Stomach Pain Fluoxetine 8/ Placebo 0/50 0 No patient dropped out of the study due to adverse events. Six patients were dropped from the initially recruited fluoxetine subjects for the following reasons: noncompliance (2), analgesic overuse (2), use of a concurrent antimigraine prophylactic (1), with one subject lost to follow-up. Eight patients were dropped from or decided to leave the initial placebo group due to drug inefficacy (3), fear of side effects (1), pregnancy (1), abnormal CT scan (1), and two subjects (one each from the migraine-placebo and CDH-fluoxetine groups) were lost to follow-up for reasons unknown. DISCUSSION In regard to headache, this study found statistically significant fluoxetine effects for Overall Headache Status (VAS), Headache-Free Days, and Double-Blind Investigator Judgement for chronic daily headache but not intermittent migraine. Significant treatment effects did not emerge until the third month on fluoxetine (second month on adjusted dose). By the end of the study, the fluoxetine group showed an additional statistically significant 53% improvement in Overall Headache Status above the level at the end of the single-blind placebo period, in contrast to only 17% additional improvement for the double-blind placebo group. With the exception of the modest increase in Headache-Free Days, fluoxetine did not differentially affect headache measures of severity and overall headache index based on the Headache Diary, considered the "gold standard" of headache assessment.13 Although availability and limits on use of rescue medications remained constant throughout the study, such abortives might be expected to place an upper limit on measures of headache severity and duration, and would therefore be expected to affect a combined measure such as headache index. Consequently, measures of headache frequency (eg Headache-Free Days) may in fact be the most reliable parameter from the Headache Diary under the current experimental design. Our results suggest that the overall impact of fluoxetine on headache in CDH sufferers was associated with an impact on mood. Fluoxetine had a significant effect on overall Mood beginning in the second month, further increasing in the third month of treatment. As noted, headache improvement was not observed until the end of the third month. Mood improvement was a precursor of headache improvement: those patients who showed Mood improvement in the second month were most likely to report headache improvement in the third month. It should be noted that Mood and Overall Headache Status were both measured in the same way (Visual Analogue Scale). Due to shared method variance, we would expect higher correlations between Mood and the VAS measure of headache than between Mood and Headache Diary measures. However, significant Mood improvement in the month prior to improvement in headache ratings, as well as borderline to significant correlations between Mood and Headache-Free Days for CDH patients (ranging from R=.328, P=.083 to R=.526, P=.003 over the experimental phases) argue against method variance as the sole explanation of the Mood-headache connection. Over 85% of the patients had initial Beck Depression scores within normal limits. Mood and headache improvement were not limited to depressed patients, and Beck scores did not predict treatment outcome. However, depression is not uncommon in headache patients. Epidemiological research has
6 shown a higher rate of major depression in migraine (27%) than in the nonmigraine population (9%).15 Since its introduction in 1988, over 11,000 patients have participated in clinical trials of fluoxetine throughout the world, with convincing evidence of its efficacy for treating depression.16 It remains possible that fluoxetine may be most beneficial to the chronic daily headache patient or even migraine patient with comorbid depression. This area merits further research. Fluoxetine was well tolerated at 40 mg by 86% (migraine) to 90% (CDH) of the patients, with no dropouts due to adverse events. Controlled studies for depression have found that patients can tolerate higher doses, in the mg range.17,18 Results for headache may be greater with higher doses, another area worthy of future research exploration. In summary, fluoxetine appears moderately effective for prophylaxis of CDH but not migraine, with a generally tolerable side effect profile. Pending further research, its use as an alternative pharmacotherapy for patients with chronic daily headache, including those unable to tolerate adverse effects from other medications, appears justifiable at this time. Acknowledgment: Appreciation is extended to the Eli Lilly Company for financial support. REFERENCES 1. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993; 13: Fozard JR. 5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology. In: Sandler M, Collins GM. editors. Migraine: a spectrum of ideas. New York: Oxford University Press, 1990; Raskin NH. Headache. 2nd Ed. New York: Churchill Livingstone, 1988: Diamond S, Freitag FG. The use of fluoxetine in the treatment of headache. Clin J Pain 1989; 5: Hynes MD, Lochner MA, Bemis KG, Hymson DL. Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors. Life Sci 1985; 36: Eisendrath S J, Kodama KT. Fluoxetine management of chronic abdominal pain. Psychosomatics 1992; 33: Petitto JM, Mundle LB, Nagy BR, et al. Improvement of arthritis with fluoxetine. Psychosomatics 1992; 33: Power-Smith P, Turkington D. Fluoxetine in phantom limb pain. Br J Psychiatry 1993;163: Sullivan M. Integrated treatment of a woman with chronic hand pain. Hosp Community Psychiatry 1991; 42: Theesen KA, Marsh WR. Relief of diabetic neuropathy with fluoxetine. DICP 1989; 23: Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: International Headache Society. Headache Classification Committee. Proposed classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8(suppl 7): Blanchard EB, Andrasik F, Neff DF et al. Social validation of the headache diary. Behav Ther 1981; 12: Beck AT. Depression inventory. Philadelphia: Center for Cognitive Therapy, Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiat Res 1991; 37: Stokes PE. Fluoxetine: a five-year review. Clinical Therapeutics 1993; 15: Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in out-patients with major depressive disorder. J Clin Psychiatry 1985; 46: Usher RW, Beasley CM, Bosomworth JC. Efficacy and safety of morning versus evening fluoxetine administration. J Clin Psychiatry 1991; 52:
PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationBOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required]
BOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required] Medical Policy: MP-RX-01-11 Original Effective Date: March 24, 2011 Reviewed: Revised: This policy applies to products
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationFrequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice
DISEASE STATE REVIEW Course of Frequent/Daily Headache in the General Population and in Medical Practice Egilius L.H. Spierings, MD, PhD, Willem K.P. Mutsaerts, MSc Department of Neurology, Brigham and
More informationROUNDTABLE DISCUSSION
THE ROLE OF OPIOID THERAPY IN MANAGING CHRONIC DAILY HEADACHE * The following includes a summary of a roundtable discussion with panel members Joel R. Saper, MD ; John F. Rothrock, MD ; and Jeffrey D.
More informationindicates that the relationship between psychosocial distress and disability in patients with CLBP is not uniform.
Chronic low back pain (CLBP) is one of the most prevalent health problems in western societies. The prognosis of CLBP is poor, as indicated by very low rate of resolution, even with treatment. In CLBP,
More informationTension Type Headaches
Tension Type Headaches Research Review by : Dr. Ian MacIntyre Physiotherapy for tension-type Headache: A Controlled Study P. Torelli, R. Jenson, J. Olsen: Cephalalgia, 2004, 24, 29-36 Tension-type headache
More informationTension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationTension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationHeadache - What is Your Migraine Size?
Headache The Pharmacist s Role in Assessment & Peter Loewen, B.Sc.(Pharm), Pharm.D. Vancouver Hospital & Health Sciences Centre University of British Columbia ETC, Headache. Nan Quintin www.vhpharmsci.com
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
More information33 % of whiplash patients develop. headaches originating from the upper. cervical spine
33 % of whiplash patients develop headaches originating from the upper cervical spine - Dr Nikolai Bogduk Spine, 1995 1 Physical Treatments for Headache: A Structured Review Headache: The Journal of Head
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of
More informationMajor Depression. What is major depression?
Major Depression What is major depression? Major depression is a serious medical illness affecting 9.9 million American adults, or approximately 5 percent of the adult population in a given year. Unlike
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationHeadaches and Kids. Jennifer Bickel, MD Assistant Professor of Neurology Co-Director of Headache Clinic Children s Mercy Hospital
Headaches and Kids Jennifer Bickel, MD Assistant Professor of Neurology Co-Director of Headache Clinic Children s Mercy Hospital Overview Headache classifications and diagnosis Address common headache
More informationTreatment of Prescription Opioid Dependence
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
More informationBehavioral and Physical Treatments for Tension-type and Cervicogenic Headache
Evidence Report: Behavioral and Physical Treatments for Tension-type and Cervicogenic Headache Douglas C. McCrory, MD, MHSc Donald B. Penzien, PhD Vic Hasselblad, PhD Rebecca N. Gray, DPhil Duke University
More informationAwide choice of pharmacotherapies is
NONPHARMACOLOGIC PREVENTION AND TREATMENT OF RECURRENT HEADACHE * Donald B. Penzien, PhD, Mary G. Gabb, MS ABSTRACT Nonpharmacologic therapies play an important role in the prevention and treatment of
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. April 20, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call April 20, 2011 Case Presentations SUNY Downstate Bronx-Lebanon East Bay AIDS Center HCV Treatment Patient Safety Monitoring: Beyond
More informationDepression & Chronic Pain
Depression & Chronic Pain Daniel Duhigg, DO, MBA Assistant Professor, Department of Psychiatry Adjunct Assistant Professor, Department of Neurology University of New Mexico Health Sciences Center New Mexico
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationNational Hospital for Neurology and Neurosurgery. Migraine associated dizziness Department of Neuro-otology
National Hospital for Neurology and Neurosurgery Migraine associated dizziness Department of Neuro-otology If you would like this document in another language or format or if you require the services of
More informationUpdate on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
More informationPrednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study
Brief Report Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study Cephalalgia 33(3) 202 207! International
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationEmergency and inpatient treatment of migraine: An American Headache Society
Emergency and inpatient treatment of migraine: An American Headache Society survey. The objective of this study was to determine the practice preferences of AHS members for acute migraine treatment in
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationHEADACHES IN CHILDREN AND ADOLESCENTS. Brian D. Ryals, M.D.
HEADACHES IN CHILDREN AND ADOLESCENTS Brian D. Ryals, M.D. Frequency and Type of Headaches in Schoolchildren 8993 children age 7-15 in Sweden Migraine in 4% Frequent Nonmigrainous in 7% Infrequent Nonmigrainous
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN
Janice K. Brewer Governor Arizona State Board of Nursing 4747 North 7 th Street, Suite 200 Phoenix, AZ 85014-3655 Phone (602) 889-5150 Fax - (602) 889-5155 E-Mail: arizona@azbn.gov Home Page: http://www.azbn.gov
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationEfficacy of a Comprehensive Pain Rehabilitation Program. A Longitudinal Study. Cognitive-behavioral approach. Mayo Clinic Pain Rehabilitation Center
Efficacy of a Compreheive Pain Rehabilitation Program with Opioid Withdrawal: A Longitudinal Study Connie Luedtke, MA, RN-BC Mayo Clinic Pain Rehabilitation Center Luedkte.connie@mayo.edu www.mayoclinic.org/pain-rehabilitation-center-rst/
More informationGuidelines for trials of drug treatments in tension-type headache
Guidelines for trials of drug treatments in tension-type headache First Edition: International Headache Society Committee on Clinical Trials in Tension-type Headache COMMITTEE MEMBERS J SCHOENEN, Belgium
More informationBest Practices Treatment Guideline for Major Depression
Best Practices Treatment Guideline for Major Depression Special Report on New Depression Treatment Technology Based on 2010 APA Practice Guidelines Best Practices Guideline for the Treatment of Patients
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More information1. Which of the following SSRIs requires up to a 5-week washout period because of the
1 Chapter 38. Major Depressive Disorders, Self-Assessment Questions 1. Which of the following SSRIs requires up to a 5-week washout period because of the long half-life of its potent active metabolite?
More informationUpdated guidelines on headache management for use by the pharmacist
M I P C A MIGRAINE IN PRIMARY CARE ADVISORS Updated guidelines on headache management for use by the pharmacist Introduction N U M B E R 2 1, O C T O B E R 2 0 1 2 Headache is a major public health problem,
More informationEvaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential
More informationREPORTING ON PARTICIPANT DISPOSITION IN CLINICAL TRIALS. Dennis C. Turk, Ph.D. 1 University of Washington School of Medicine
1 REPORTING ON PARTICIPANT DISPOSITION IN CLINICAL TRIALS Dennis C. Turk, Ph.D. 1 University of Washington School of Medicine Running head: Patient Disposition 1 Preparation of this manuscript was supported
More informationDepression Screening in Primary Care
Depression Screening in Primary Care Toni Johnson, MD Kristen Palcisco, BA, MSN, APRN MetroHealth System Our Vision Make Greater Cleveland a healthier place to live and a better place to do business. 2
More informationMULTIPLE SCLEROSIS AND DEPRESSION. Michael Racke, MD The Ohio State University Meera Narasimhan, MD University of South Carolina
MULTIPLE SCLEROSIS AND DEPRESSION Michael Racke, MD The Ohio State University Meera Narasimhan, MD University of South Carolina MICHAEL RACKE, MD Disclosures!! Research/Grants: National Institute of Neurologic
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationWhen the Pain Won t Stop: Managing Chronic Daily Headache
When the Pain Won t Stop: Managing Chronic Daily Headache Arnolda Eloff, MB, ChB, Mmed Presented at the University of Calgary s Wednesday Evening Course Program, Calgary, Alberta. Copyright Chronic daily
More informationViews and Perspectives
Headache 2010 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2010.01764.x Published by Wiley Periodicals, Inc. Views and Perspectives Defining the Pharmacologically Intractable Headache
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationMARKET ANALYSIS of ActiPatch Therapy Try & Tell Surveys
MARKET ANALYSIS of ActiPatch Therapy Try & Tell Surveys Consumers Report Pain Relief, Product Satisfaction and Intent to Buy New Behavior in Pain Management is Developing BioElectronics Corporation 4539
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationACUTE EFFECTS OF LORATADINE, DIPHENHYDRAMINE AND PLACEBO, ALONE AND WITH ALCOHOL, ON SKILLS PERFORMANCE
ACUTE EFFECTS OF LORATADINE, DIPHENHYDRAMINE AND PLACEBO, ALONE AND WITH ALCOHOL, ON SKILLS PERFORMANCE C. Jeavons Wilkinson and Herbert Moskowitz University of California at Los Angeles (UCLA) and Southern
More informationplacebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
More informationIMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:
Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationDrug Class Review Neuropathic Pain
Drug Class Review Neuropathic Pain Final Update 1 Report June 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize key information
More informationAlcohol Use and Dependency Among Senior Women ~ The Hidden Epidemic
Alcohol Use and Dependency Among Senior Women ~ The Hidden Epidemic Frederic C. Blow, Ph.D. Professor of Psychiatry University of Michigan Medical School Ann Arbor, Michigan USA Disclosure Dr. Blow receives
More informationMichigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain
JENNIFER M. GRANHOLM GOVERNOR STATE OF MICHIGAN DEPARTMENT OF COMMUNITY HEALTH LANSING JANET OLSZEWSKI DIRECTOR Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment
More informationPrevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy
Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy International Society for Sexual Medicine 2014 Presenter: Felipe Borges
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationTracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute. 503-346-1183 walkertr@ohsu.edu
Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute 503-346-1183 walkertr@ohsu.edu Exercise Questions to Keep in Mind Is there an adverse event? What is the severity? What is the relationship
More informationIn 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationBackground & Significance
The Impact Of A Structured Opioid Renewal Clinic On Aberrant Drug Behavior Outcomes At A Northeastern VA Medical Center Salimah H. Meghani, PhD, MBE, CRNP Assistant Professor, University of Pennsylvania
More informationTHE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationMigraine The Problem: Common Symptoms:
Migraine The Problem: A combination of genetic and environmental factors alter pain mechanisms in your brain Transient changes in brain chemicals such as serotonin and neuropeptides affect the membranes
More informationPERIODIC TRIGGER POINT INJECTIONS UP TO 4 PER YEAR: Upheld
Case Number: CM13-0037615 Date Assigned: 12/18/2013 Date of Injury: 05/14/2001 Decision Date: 04/21/2014 UR Denial Date: 10/14/2013 Priority: Standard Application Received: 10/23/2013 HOW THE IMR FINAL
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 March 2003 CPMP/EWP/785/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More information(4) To characterize the course of illness after adequate response to and continuation on the treatments found effective for individual participants.
I. Specific Aims/Objectives STAR*D has several main objectives and is powered to assess the effectiveness of a sequence of treatments at various levels of treatment. Most of these objectives entail evaluating
More informationNaltrexone and Alcoholism Treatment Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
More informationTest Content Outline Effective Date: June 9, 2014. Pain Management Nursing Board Certification Examination
Pain Management Nursing Board Certification Examination There are 175 questions on this examination. Of these, 150 are scored questions and 25 are pretest questions that are not scored. Pretest questions
More information